## IAP15 Rec'd PCT/PTO 13 APR 2006

Docket No.: 65350US(54086)

(PATENT)

## IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US) (National Phase of International Appln.: PCT/AU2004/001416 Publication No. WO2005/037308 A1)

In re Patent Application of:

Michael V. Agrez

International Application No.:PCT/AU2004/001416

International filing Date: October 15, 2004

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: METHODS AND AGENTS FOR THE

TREATMENT OF CANCER

**Examiner: Not Yet Assigned** 

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicants invite the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicant respectfully requests that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new U.S. national phase patent application of PCT/AU2004/001416, filed October 15, 2004, submitted herewith.

Those documents that are marked with a double asterisk (\*\*) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they have previously been transmitted by the International Bureau, along with the International Search

Docket No.: 65350US(54086)

Application No. Not Yet Assigned US National Phase of PCT/AU2004/001416 Filed October 15, 2004 Preliminary Amendment

Report, to all the Designated Offices in corresponding international patent application No. PCT/AU2004/001416. Copies of the International Search Report and the International Preliminary Report on Patentability are enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Applicant submits that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Applicant believes that no fees are due for consideration and entry of this Information Disclosure Statement. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 65350US(54086). A duplicate copy of this paper is enclosed.

Dated: April 13, 2006

Peter C. Lauro, Esq.

Respectfully submitted

Registration No.: 32,360

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

## LAP15 Ros'd PCT/TTO 13 APR 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO						
				Application Number	Not Yet Assigned 10/57	5736
INFORMATION DISCLOSURE				Filing Date	Concurrently Herewith	
S	TATEMENT I	BY A	APPLICANT	First Named Inventor	Michael V. Agrez	
				Art Unit	N/A	
(Use as many sheets as necessary)			necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	65350US(54086)	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA**	US-6 312 956-B1	11-06-2001	LANE	Whole document

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)		Applicant of Cited Document	or Relevant Figures Appear	T⁵
	BA**	-WO 2001/000677-A	01-04-2001	THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOC. LTD.	Whole document	
	BB**	-WO 2002/051993-A	07-04-2002	THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOC. LTD.	Whole document	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER 65350US(54086)					
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371	U.S. APPLICATION NO TRANSPER STOCKE 12					
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED					
PCT/AU2004/001416 15 October 2004	17 October 2003					
TITLE OF INVENTION  METHODS AND AGENTS FOR THE TREATMENT OF CANCER						
APPLICANT(S) FOR DO/EO/US						
Michael V. Agrez  Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:						
1. x This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.						
2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.						
This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4. The US has been elected (Article 31).						
5. X A copy of the International Application as filed (35 U.S.C. 371 (c)(2))	•					
a. is attached hereto (required only if not communicated by the Internati	onal Bureau).					
b. x has been communicated by the International Bureau.						
c. is not required, as the application was filed in the United States Recei	iving Office (RO/US).					
6. An English language translation of the International Application as filed (3	5 U.S.C. 371(c)(2)).					
a. is attached hereto.						
b. has been previously submitted under 35 U.S.C. 154(d)(4).						
7. X Amendments to the claims of the International Application under PCT Artic	cle 19 (35 U.S.C. 371(c)(3))					
a. are attached hereto (required only if not communicated by the Interna						
b. x have been communicated by the International Bureau.						
c. have not been made; however, the time limit for making such amenda	nents has NOT expired.					
d. have not been made and will not be made.	•					
8. An English language translation of the amendments to the claims under Pe	CT Article 19 (35 U.S.C. 371(c)(3)).					
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).	`					
An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
Items 11 to 20 below concern document(s) or information included:						
11. x An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12. An assignment document for recording. A separate cover sheet in complia	ance with 37 CFR 3.28 and 3.31 is included.					
13. x A preliminary amendment.						
14. x An Application Data Sheet under 37 CFR 1.76.						
. A substitute specification.						
A power of attorney and/or change of address letter.						
A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825.						
A second copy of the published International Application under 35 U.S.C. 154(d)(4).						
A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).						